Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent - 26/08/11
Doi : 10.1016/j.amjcard.2004.06.065
Seung-Woon Rha, MD, PhD, Pramod K. Kuchulakanti, MD, Rajbabu Pakala, PhD, Edouard Cheneau, MD, Jana A. Fournadjiev, PhD, Ellen Pinnow, MS, Afework GebreEyesus, MD, George Aggrey, MD, Zuyue Wang, MD, Augusto D. Pichard, MD, Lowell F. Satler, MD, Kenneth M. Kent, MD, Joseph Lindsay, MD, Ron Waksman, MD ⁎ 
Washington Hospital Center, Washington, DC, USA
*Dr. Waksman's address is: Washington Hospital Center, 110 Irving Street, NW, Suite 4B-1, Washington, DC 20010
Riassunto |
Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
Il testo completo di questo articolo è disponibile in PDF.© 2004
Excerpta Medica Inc. Tutti i diritti riservati.
Vol 94 - N° 8
P. 1047-1050 - ottobre 2004 Ritorno al numero
Articolo precedente
- Matrix metalloproteinase-1 promoter polymorphisms and changes in left ventricular volume following acute myocardial infarction
- Thomas N. Martin, Dawn E. Penney, Jamie A. Smith, Bjoern A. Groenning, Henry J. Dargie, Graham S. Hillis
- Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries
- Young Joon Hong, Myung Ho Jeong, Weon Kim, Sang Yup Lim, Sang Hyun Lee, Seo Na Hong, Ju Han Kim, Young Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Dong Lyun Cho, Hoon Kim, Jung Chaee Kang
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?